16alpha-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis comorbidity treatment. Lopez-Torres MO, Marquina-Castillo B, Ramos-Espinosa O, Mata-Espinosa D, et al. Clin Exp Immunol 2021 Apr 18. doi: 10.1111/cei.13603.

Read + Share

Amedeo Smart

Independent Medical Education

Lopez-Torres MO, Marquina-Castillo B, Ramos-Espinosa O, Mata-Espinosa D, et al. 16alpha-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis comorbidity treatment. Clin Exp Immunol 2021 Apr 18. doi: 10.1111/cei.13603.
PMID: 33866550